C
1.52
-0.09 (-5.77%)
| Previous Close | 1.61 |
| Open | 1.62 |
| Volume | 110,922 |
| Avg. Volume (3M) | 71,373 |
| Market Cap | 18,998,256 |
| Price / Sales | 1.23 |
| Price / Book | 4.32 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Operating Margin (TTM) | -426.77% |
| Diluted EPS (TTM) | -6.08 |
| Quarterly Revenue Growth (YOY) | 14.10% |
| Current Ratio (MRQ) | 1.23 |
| Operating Cash Flow (TTM) | -33.58 M |
| Levered Free Cash Flow (TTM) | -18.95 M |
| Return on Assets (TTM) | -52.08% |
| Return on Equity (TTM) | -2,951.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Curis, Inc. | Mixed | Bearish |
AIStockmoo Score
0.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.17 |
|
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.64% |
| % Held by Institutions | 44.65% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2025 | Announcement | Curis Provides Third Quarter 2025 Business Update |
| 30 Oct 2025 | Announcement | Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025 |
| 03 Oct 2025 | Announcement | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 02 Sep 2025 | Announcement | Curis to Present at Upcoming Healthcare Conferences in September |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |